Edition:
United States

Seattle Genetics Inc (SGEN.OQ)

SGEN.OQ on NASDAQ Stock Exchange Global Select Market

46.30USD
18 Aug 2017
Change (% chg)

$-0.07 (-0.15%)
Prev Close
$46.37
Open
$46.44
Day's High
$47.35
Day's Low
$46.06
Volume
256,904
Avg. Vol
387,474
52-wk High
$75.13
52-wk Low
$42.59

SGEN.OQ

Chart for SGEN.OQ

About

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company's marketed product ADCETRIS, or brentuximab... (more)

Overall

Beta: 2.41
Market Cap(Mil.): $6,622.16
Shares Outstanding(Mil.): 143.03
Dividend: --
Yield (%): --

Financials

  SGEN.OQ Industry Sector
P/E (TTM): -- 78.89 32.56
EPS (TTM): -1.43 -- --
ROI: -29.99 2.83 14.89
ROE: -32.73 5.09 16.13

BRIEF-FDA accepts supplemental biologics license application and grants priority review for adcetris in cutaneous t-cell lymphoma

* FDA accepts supplemental biologics license application and grants priority review for adcetris® (brentuximab vedotin) in cutaneous t-cell lymphoma

Aug 16 2017

BRIEF-Seattle Genetics to buy Bothell plant from Bristol-Myers Squibb

* Seattle Genetics announces purchase of Bothell manufacturing facility from Bristol-Myers Squibb

Aug 01 2017

BRIEF-Seattle Genetics Q2 loss per share $0.39

* Seattle Genetics reports second quarter 2017 financial results

Jul 27 2017

BRIEF-Seattle Genetics Inc says Health Canada has issued a non-conditional marketing authorization for use ofadcetris

* Seattle Genetics Inc says Health Canada has issued a non-conditional marketing authorization for use ofadcetris

Jul 25 2017

BRIEF-Seattle Genetics announces clinical collaboration to expand the therapeutic evaluation of sgn-liv1a

* Seattle Genetics announces clinical collaboration to expand the therapeutic evaluation of sgn-liv1a in triple negative breast cancer

Jul 24 2017

BRIEF-Seattle Genetics reports 8.2 percent stake in Immunomedics as of June 29, 2017

* Seattle genetics inc reports a 8.2 percent stake in immunomedics inc as of June 29, 2017 - sec filing

Jul 07 2017

Seattle Genetics slumps as cancer drug data fails to impress

Seattle Genetics Inc's lymphoma drug met the main goal in a late stage study, but shares of the company tumbled as the data fell short of investor expectations on the treatment's advantages over standard of care.

Jun 26 2017

UPDATE 2-Seattle Genetics slumps as cancer drug data fails to impress

* Investors focus on narrow drug benefits vs standard of care

Jun 26 2017

CORRECTED-UPDATE 1-Seattle Genetics, Takeda lymphoma drug success fails to impress investors

June 26 Seattle Genetics Inc and Japan's Takeda Pharmaceutical Co Ltd said on Monday that their drug met the main goal in a late-stage study of helping blood cancer patients live longer without their condition worsening.

Jun 26 2017

Seattle Genetics halts late-stage study of leukemia drug (June 19)

(The story corrects the last paragraph in the June 19 story to say Adcetris generated $266 million in sales last year, not $71 million)

Jun 26 2017

Competitors

  Price Chg
Millennium Pharmacon Internationl Tbk PT (SDPC.JK) Rp. 119.00 +1.00
Eisai Co., Ltd (4523.T) ¥5,612 -81.00
Pfizer Inc. (PFE.N) $32.67 -0.28
Novartis AG (NOVN.S) CHF79.80 -0.85
Merck & Co., Inc. (MRK.N) $61.49 -0.32
Bayer AG (BAYGn.DE) €107.90 -0.20
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €82.26 -0.50
GlaxoSmithKline plc (GSK.L) 1,490.00 -16.00
Eli Lilly and Co (LLY.N) $77.07 -0.73

Earnings vs. Estimates